CoChat

Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects

Open access
Nagaraj, Siranjeevi, Laskowska-Kaszub, Katarzyna, Dębski, Konrad J., Wojsiat, Joanna, Dąbrowski, Michał, Gabryelewicz, Tomasz, Kuźnicki, Jacek, Wojda, Urszula · 2017 · Oncotarget
Cited by 146

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

// Siranjeevi Nagaraj 1,* , Katarzyna Laskowska-Kaszub 1,* , Konrad J. Dębski 2 , Joanna Wojsiat 1 , Michał Dąbrowski 2 , Tomasz Gabryelewicz 3 , Jacek Kuźnicki 4 and Urszula Wojda 1 1 Laboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology of Polish Academy of Sciences, Warsaw, Poland 2 Laboratory of Bioinformatics, Nencki Institute of Experimental Biology of Polish Academy of Sciences, Warsaw, Poland 3 Department of Neurodegenerative Disorders, Mossakowski Medical Research Center, Warsaw, Poland 4 Laboratory of Neurodegeneration, International Institute of Molecular and Cell Biology, Warsaw, Poland * These authors have contributed equally to this work Correspondence to: Urszula Wojda, email: // Keywords : Alzheimer`s disease, early Alzheimer’s disease, mild cognitive impairment, microRNA, biomarker, Gerotarget Received : October 07, 2016 Accepted : January 16, 2017 Published : February 05, 2017 Abstract Alzheimer’s disease (AD) is the most common age-related dementia. Among its major challenges is identifying molecular signatures characteristic for the early AD stage in patients with Mild Cognitive Impairment (MCI-AD), which could serve for deciphering the AD pathomechanism and also as non-invasive, easy-to-access biomarkers. Using qRT-PCR we compared the microRNA (miRNA) profiles in blood plasma of 15 MCI-AD patients, whose diagnoses were confirmed by cerebrospinal fluid (CSF) biomarkers, with 20 AD patients and 15 non-demented, age-matched individuals (CTR). To minimize methodological variability, we adhered to standardization of blood and CSF assays recommended by the international Joint Programming for Neurodegenerative Diseases (JPND) BIOMARKAPD consortium, and we employed commercially available Exiqon qRT-PCR-assays. In the first screening, we assessed 179 miRNAs of plasma. We confirmed 23 miRNAs reported earlier as AD biomarker candidates in blood and found 26 novel differential miRNAs between AD and control subjects. For representative 15 differential miRNAs, the TargetScan, MirTarBase and KEGG database analysis indicated putative protein targets among such AD hallmarks as MAPT (Tau), proteins involved in amyloidogenic proteolysis, and in apoptosis. These 15 miRNAs were verified in separate, subsequent subject groups. Finally, 6 miRNAs (3 not yet reported in AD context and 3 reported in AD blood) were selected as the most promising biomarker candidates differentiating early AD from controls with the highest fold changes (from 1.32 to 14.72), consistent significance, specificities from 0.78 to 1 and sensitivities from 0.75 to 1. (patent pending, PCT/IB2016/052440).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15109

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 146

Metadata

Authors
Nagaraj, S., Laskowska-Kaszub, K., Dębski, K. J., Wojsiat, J., Dąbrowski, M., Gabryelewicz, T., Kuźnicki, J., & Wojda, U.
Venue
Oncotarget
Published
2017-02-05
Volume
8
Issue
10
Pages
16122-16143
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2586834816
Cited by
146
References
19
FWCI
4.99
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.